CEL-SCI Corp (CVM)
1.23
0.00 (0.00%)
USD |
NYAM |
Jun 25, 16:00
1.23
0.00 (0.00%)
After-Hours: 20:00
CEL-SCI Research and Development Expense (Annual): 22.47M for Sept. 30, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| September 30, 2023 | 22.47M |
| September 30, 2022 | 25.36M |
| September 30, 2021 | 23.11M |
| September 30, 2020 | 17.84M |
| September 30, 2019 | 12.66M |
| September 30, 2018 | 10.91M |
| September 30, 2017 | 15.61M |
| September 30, 2016 | 17.45M |
| September 30, 2015 | 19.19M |
| September 30, 2014 | 15.27M |
| September 30, 2013 | 12.68M |
| September 30, 2012 | 10.37M |
| September 30, 2011 | 11.75M |
| September 30, 2010 | 11.91M |
| September 30, 2009 | 6.012M |
| Date | Value |
|---|---|
| September 30, 2008 | 4.102M |
| September 30, 2007 | 2.528M |
| September 30, 2006 | 1.897M |
| September 30, 2005 | 2.230M |
| September 30, 2004 | 1.942M |
| September 30, 2003 | 1.916M |
| September 30, 2002 | 4.700M |
| September 30, 2001 | 7.762M |
| September 30, 2000 | 4.979M |
| September 30, 1999 | 4.50M |
| September 30, 1998 | 3.80M |
| September 30, 1997 | 6.00M |
| September 30, 1996 | |
| September 30, 1995 | 1.80M |
| September 30, 1994 | 2.90M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
12.66M
Minimum
2019
25.36M
Maximum
2022
20.29M
Average
22.47M
Median
2023
Research and Development Expense (Annual) Benchmarks
| AIM ImmunoTech Inc | 10.94M |
| IGC Pharma Inc | 3.461M |
| NovaBay Pharmaceuticals Inc | 0.068M |
| Protalix BioTherapeutics Inc | 17.09M |
| Palatin Technologies Inc | 22.63M |